Feedback / Questions
CNP520 - Novartis, Amgen
amilomotide (CAD106) - Novartis
CAD-106 + CNP520: Completion of P2b/3 GENERATION S1 trial (NCT02565511) in Alzheimer's disease in 2025
(Novartis)
-
Apr 24, 2019 -
Q1 2019 Results
Trial completion date
https://www.novartis.com/sites/www.novartis.com/files/q1-2019-ir-presentation.pdf
Apr 24, 2019
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious